This inventor holds 2 USPTO granted patents. Top assignees: Unversität Zürich, Massachusetts Institute of Technology. Active years: 2011-2024.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Location History:
- Zurich, CH (2011)
- Zürich, CH (2024)
Company Filing History:
2 out of 276 
1 out of 8,586 
Years Active: 2011-2024
Title: The Innovative Journey of Marco Wachtel
Introduction: Marco Wachtel, a notable inventor based in Zürich, Switzerland, has made significant contributions to the field of pharmaceuticals. With his groundbreaking work focusing on small molecule binders of the oncogenic fusion transcription factor PAX3-FOXO1, Wachtel's innovations are poised to make a substantial impact on cancer treatment methodologies.
Latest Patents: Marco Wachtel holds a patent for his invention titled "Small molecule binders of the oncogenic fusion transcription factor PAX3-FOXO1." This patent encompasses compounds characterized by the general formula P-L-U, or their pharmaceutically acceptable salts. In this formulation, P represents a FOXO1 fusion protein binding moiety, L serves as a bivalent linker, and U is identified as an ubiquitin ligase binding moiety. Moreover, the patent details pharmaceutical compositions that incorporate these compounds and outlines methods for their utilization in medical therapies.
Career Highlights: Throughout his career, Marco Wachtel has been associated with prestigious institutions such as the Massachusetts Institute of Technology and Universität Zürich. His time at these institutions has provided him with a robust foundation in research and development, enabling him to pursue innovative solutions in the pharmaceutical sector.
Collaborations: One of Marco Wachtel's notable collaborations has been with Shelby Doyle. Working alongside skilled professionals enhances the inventive process and fosters a deeper exploration of ideas that can lead to groundbreaking innovations.
Conclusion: Marco Wachtel's dedication to research and invention reflects his commitment to advancing the medical field through innovative pharmaceutical solutions. With his patent on small molecule binders of the oncogenic fusion transcription factor PAX3-FOXO1, he stands as a promising contributor to future oncology treatments. His work exemplifies the vital role of inventors in driving scientific progress and shaping the future of medicine.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile